Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men

NCT ID: NCT02599701

Last Updated: 2016-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the effects of gabapentin in sleep polysomnography parameters and in nocturnal secretion of endogenous hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary-gonadal (HPG) and somatotropic axes hormones and basal IGF-1 in older men.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The influence of sleep variables on muscle protein anabolism is little studied, but data on the effects of slow-wave sleep and the syndrome of obstructive sleep apnea on the hypothalamic-pituitary axis indicate that interventions in the sleep structure and disorders impact on the age-related muscle loss. Thus, we propose to assess the acute effects of a drug potentially capable of increasing slow wave sleep, and consequently growth hormone release during sleep, on the physiological release of growth hormone, testosterone and IGF-1 during the night in older healthy men.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

A single dose of placebo with exactly the same characteristics of the active drug at bedtime.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

A single placebo dose with the same physical characteristics of the active intervention.

Gabapentin

A single dose of Gabapentin 300mg at bedtime.

Group Type EXPERIMENTAL

Gabapentin

Intervention Type DRUG

A single dose Gabapentin 300mg at bedtime.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gabapentin

A single dose Gabapentin 300mg at bedtime.

Intervention Type DRUG

Placebo

A single placebo dose with the same physical characteristics of the active intervention.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neurontin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 60 years old or more,
* healthy men

Exclusion Criteria

* Basal Apnea-Hypopnea index (aHI)\>=15
* Restless Legs Syndrome Symptons
* BMI less than 18.5 kg/m2 or greater than 30 kg/m2
* Less than 30 min. of regular physical activity (at least walking inside home, etc.)
* Plasma albumin below 3.5 mg/dL
* Psychoactive drugs use
* Drugs with muscle anabolic potential
* Current treatment for obesity or weight gain
* Enteral or parenteral feeding
* Inability to walk without assistance,
* Loss of independence in any activity of daily living
* Nocturia above 2 episodes
* Smoking more than 2 cigarettes per day
* Alcoholism (more than 2 doses a day)
* Prior epilepsy diagnosis
* Clinically evident atherosclerotic disease
* Dementia
* Depression
* Rheumatic diseases
* Cancer
* Diabetes (poorly controlled, HbA1C \> 7,0, requirement of insulin)
* Thyroid dysfunction without treatment
* Advanced stages in COPD, HF, liver or renal failure
Minimum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associação Fundo de Incentivo à Pesquisa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dalva Poyares

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sergio Tufik, PhD

Role: STUDY_CHAIR

AFIP - Associação Fundo de Incentivo a Pesquisa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto do Sono

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev. 2012 Jun;33(3):314-77. doi: 10.1210/er.2012-1002. Epub 2012 Mar 20.

Reference Type BACKGROUND
PMID: 22433122 (View on PubMed)

Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998 Dec;19(6):717-97. doi: 10.1210/edrv.19.6.0353.

Reference Type BACKGROUND
PMID: 9861545 (View on PubMed)

Dattilo M, Antunes HK, Medeiros A, Monico Neto M, Souza HS, Tufik S, de Mello MT. Sleep and muscle recovery: endocrinological and molecular basis for a new and promising hypothesis. Med Hypotheses. 2011 Aug;77(2):220-2. doi: 10.1016/j.mehy.2011.04.017. Epub 2011 May 7.

Reference Type BACKGROUND
PMID: 21550729 (View on PubMed)

Penev P, Spiegel K, L'Hermite-Baleriaux M, Schneider R, Van Cauter E. Relationship between REM sleep and testosterone secretion in older men. Ann Endocrinol (Paris). 2003 Apr;64(2):157. No abstract available.

Reference Type BACKGROUND
PMID: 12773954 (View on PubMed)

Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, Weiss R, Mockel J, Legros JJ, Copinschi G. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004 Jun;14 Suppl A:S10-7. doi: 10.1016/j.ghir.2004.03.006.

Reference Type BACKGROUND
PMID: 15135771 (View on PubMed)

Saletu M, Anderer P, Saletu-Zyhlarz GM, Parapatics S, Gruber G, Nia S, Saletu B. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm (Vienna). 2010 Apr;117(4):463-73. doi: 10.1007/s00702-009-0361-3. Epub 2010 Jan 5.

Reference Type BACKGROUND
PMID: 20049491 (View on PubMed)

Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002 Dec;43(12):1493-7. doi: 10.1046/j.1528-1157.2002.21002.x.

Reference Type BACKGROUND
PMID: 12460250 (View on PubMed)

Rosenberg KP. Gabapentin for chronic insomnia. Am J Addict. 2003 May-Jun;12(3):273-4. No abstract available.

Reference Type BACKGROUND
PMID: 12851024 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AFIP06/2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.